Health Plans

Medical-Benefit Rebate Management for Health Plans

Pharmacy benefit rebates are usually well-managed. Medical-benefit specialty rebates — tied to drugs administered under the medical benefit — often aren't. VativoRx brings the same rigor to the medical side without touching your PBM relationships.

Schedule a Discovery Call
The Challenge

Where Medical-Benefit Visibility Breaks Down

PBM rebates are contractually defined and typically tracked at a detailed level. Medical-benefit activity — buy-and-bill drugs, specialty infusion, biologics administered in clinical settings — is frequently harder to isolate, harder to validate, and harder to explain to finance and compliance stakeholders.

That visibility gap doesn't just affect the rebate opportunity. It affects how confidently your team can explain specialty cost behavior to leadership.

What We Do

How VativoRx Supports Health Plans

VativoRx helps health plans establish a structured, phased path to medical-benefit rebate visibility. The approach is built around finance-grade transparency — drug-level clarity, consistent validation, and reporting that finance, compliance, and pharmacy leadership can each use without translation.

Phase 1 is scoped as an evaluation, not a commitment. The goal is to confirm what's there before structuring an ongoing engagement.

Your Environment Stays Intact
Your PBM relationships stay in place
No EMR integration or PHI required
No vendor replacement or disruption
+
What VativoRx Adds
Phase 1 evaluation designed to confirm opportunity before expanding scope
CMS-aligned, claim-level validation methodology
Medical-benefit reporting structured for finance, compliance, and pharmacy leadership
Phased implementation aligned to your review cycles
Implementation Path

Implementation Path

Most engagements ask you to commit before you know what you have. This one doesn't.

01
Discovery & Scope
Define the medical-benefit claim environment and Phase 1 parameters — no commitment required at this stage.
No commitment
02
Data Alignment
Structured data intake — no PHI, no EMR access required. Claim data is scoped and formatted for review.
No PHI required
03
Phase 1 Analysis
Validation and reporting delivered on the agreed timeline. Finance-ready output with drug-level detail.
Finance-ready output
04
Phase 2 Decision
Phase 1 findings drive the decision — expand, continue at current scope, or conclude. The next step is yours to define.
Your decision

Find Out What Your Medical-Benefit Claims Are Missing

A scoped Phase 1 evaluation is the lowest-risk way to answer that question. No PBM disruption, no long-term commitment until you've seen the picture.

Schedule a Discovery Call →